Eli Lilly Stock Update: What Investors Should Watch in 2025

Jan 25, 2025 · Investors might keep in mind that Eli Lilly still projects substantial top-line growth for 2024 and especially for 2025. The company expects $45 billion in revenue for 2024 and somewhere in the range of $58 billion to $61 billion for 2025. Helping to drive this growth is Eli …

CouponFollow Extension

$45
OFF

Eli Lilly Stock Update: What Investors Should Watch In 2025

2 weeks from now

marketbeat.com

$45
OFF

Eli Lilly Stock: What Investors Should Watch In 2025

2 weeks from now

Jan 29, 2025 · Investors might keep in mind that Eli Lilly still projects substantial top-line growth for 2024 and especially for 2025. The company expects $45 billion in revenue for 2024 and …

investing.com

37%
OFF

Eli Lilly (LLY) Stock Price Prediction And Forecast 2025-2030

2 weeks from now

Jan 17, 2025 · We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to …

247wallst.com

5%
OFF

Eli Lilly Stock: What's There To Like? - Investor's Business Daily

2 weeks from now

Jan 15, 2025 · There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its fourth-quarter sales guidance by 5%. ↑ X The Weight-Loss …

investors.com

90%
OFF

Eli Lilly Stock Could Have A Huge Growth Catalyst In Early 2025

2 weeks from now

Dec 12, 2024 · Eli Lilly (LLY 2.90%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also …

fool.com

25%
OFF

Is Eli Lilly A Buy? Analyst Confidence Grows For 2025 - MarketBeat

2 weeks from now

Nov 5, 2024 · Eli Lilly's price pullback presents investors with an opportunity. The stock has a healthy 25% upside from critical support targets. Despite tepid results, analysts' consensus is …

marketbeat.com

8%
OFF

Should You Buy The Dip In Eli Lilly Stock Right Now?

2 weeks from now

Jan 19, 2025 · Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly dropped by as much as 8% and ended the day down around 6%. Year-to …

fool.com

25%
OFF

Eli Lilly: Recent Pullback Opens Buy Window As Stock Prepares For …

2 weeks from now

Nov 6, 2024 · Eli Lilly's price pullback presents investors with an opportunity. The stock has a healthy 25% upside from critical support targets. Despite tepid results, analysts' consensus is …

investing.com

$22.50
OFF

Lilly Reassures Investors That Weight-loss Drug Demand Is Strong ...

2 weeks from now

1 day ago · Eli Lilly also forecast annual profit largely above Wall Street estimates on Thursday, saying it expects to earn between $22.50 and $24.00 per share on an adjusted basis this year.

yahoo.com

$22.05
OFF

Eli Lilly Guides FY25 In Line With Estimates - Update - Nasdaq

2 weeks from now

1 day ago · For fiscal 2025, Eli Lilly now projects earnings in a range of $22.05 to $23.55 per share and adjusted earnings in a range of $22.50 to $24.00 per share on revenues between …

nasdaq.com

32%
OFF

Eli Lilly Issues 2025 Revenue Forecast Ahead Of Market Estimates

2 weeks from now

Jan 14, 2025 · Investing.com -- Eli Lilly and Company (NYSE: LLY) has projected its full-year global revenue for 2024 to reach around $45 billion, marking a 32% increase from the prior …

investing.com

60%
OFF

Eli Lilly Stock Before Q4 Earnings: To Buy Or Not To Buy?

2 weeks from now

4 days ago · Eli Lilly and Company (LLY ... Lilly expects to produce at least 60% more salable doses of incretins in the first half of 2025 compared to last year. An update is expected on the …

zacks.com

21%
OFF

Eli Lilly Missed Sales Expectations Again. Should Investors Be …

2 weeks from now

Jan 19, 2025 · Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. ... Lilly told investors to expect 2024 revenue to land in a range between $45.4 billion and $46 …

fool.com

35%
OFF

Eli Lilly (LLY) Q4 2024 Earnings Call Transcript

2 weeks from now

2 days ago · Eli Lilly (LLY 3.35%) Q4 2024 Earnings Call Feb 06, 2025, 10:00 a.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. …

fool.com

FAQs about Eli Lilly Stock Update: What Investors Should Watch in 2025 Coupon?

Is Eli Lilly a good stock to buy?

Eli Lilly's price pullback presents investors with an opportunity. The stock has a healthy 25% upside from critical support targets. Despite tepid results, analysts' consensus is firming around the $1000 level; the outlook and pipeline are robust. Ebglyss approval in Q3 will sustain the company's growth trajectory in 2025. ...

Should you buy Eli Lilly (LLY) stock in 2025?

Here are five stocks we like better. Eli Lilly’s NYSE: LLY market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a rally because of underperformance, but the salient details are that growth is robust, driving impressive profits, and is expected to accelerate in 2025. ...

How much will Eli Lilly make in 2025?

Eli Lilly guided up to 2025 revenue of $58 to $61 billion, with analysts currently just above $58 billion. The guidance predicts sales growth of 32% for the year, and the management team actually started 2024 off with a conservative number of only $41 billion. ...

How did Lilly stock perform in 2024?

However, after a less-than-spectacular earnings report published in late October, shares of Lilly started to slide considerably. All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. ...

Is Eli Lilly & Co stock undervalued?

Current stock price is around $803.38, which may be perceived as undervalued given the company's growth prospects and recent analyst target prices ranging from $885.00 to $1,100.00. Investors should be bearish about investing in Eli Lilly and Co for these reasons: ...

Why did Eli Lilly's stock drop in Q4?

Eli Lilly and Company's stock dipped due to cutting Q4 sales targets despite a strong 2024 performance from drugs Mounjaro and Zepbound. The biopharma forecasts 2025 revenue of $58-$61 billion for 32% sales growth, driven by significant production increases in the first half. ...